Medical Pharmacology: Chapter: 13 — Opioid Analgesics -- Module: 2 — Opioid Agonists: Classification, Pharmacokinetics, and Drug Profiles

Chapter: 13 — Opioid Analgesics — Module: 2 — Opioid Agonists: Classification, Pharmacokinetics, and Drug Profiles
Tier: T3 — Clinical Reasoning

1. A 47-year-old man with opioid use disorder and schizophrenia is stable on methadone 100 mg daily and haloperidol 10 mg daily (a typical antipsychotic that blocks dopamine D2 receptors and also inhibits hERG potassium channels). Routine labs show potassium 2.9 mEq/L and magnesium 1.4 mg/dL. His ECG shows a QTc of 538 milliseconds. The treatment team debates which factor is contributing most to the QTc prolongation and which to address first. Which of the following most accurately ranks the contributing mechanisms and identifies the correct priority sequence for intervention?

A) Haloperidol is the sole contributor to QTc prolongation in this patient because methadone's hERG blockade is fully offset by its kappa receptor antagonism, which independently shortens the QT interval through a separate ion channel mechanism; the priority intervention is haloperidol dose reduction
B) Methadone's hERG blockade is the dominant contributor and cannot be modified; haloperidol and electrolyte abnormalities are minor contributors; the only effective intervention is methadone discontinuation and transition to buprenorphine, which has no cardiac channel activity
C) All three factors — methadone hERG blockade, haloperidol hERG blockade, and electrolyte deficiencies (hypokalemia and hypomagnesemia independently reduce repolarizing potassium current by decreasing electrochemical driving force and impairing hERG channel function) — contribute additively to the observed QTc prolongation; the correct priority is to address the most rapidly reversible contributors first: replete potassium to ≥4.0 mEq/L and magnesium to ≥2.0 mg/dL urgently, then reassess the QTc before making decisions about methadone or haloperidol dose adjustment
D) The QTc of 538 milliseconds in this patient requires immediate implantable cardioverter-defibrillator placement as primary prevention before any pharmacological adjustments are made, because drug-induced QTc prolongation above 500 milliseconds carries the same arrhythmic risk as congenital long QT syndrome and requires equivalent management
E) Hypokalemia is the sole clinically significant contributor because both methadone and haloperidol require co-existing electrolyte abnormalities to produce QTc prolongation; correcting potassium and magnesium will normalize the QTc completely without any medication adjustment

ANSWER: C

Rationale:

This question asked you to analyze a multi-factorial QTc prolongation scenario and determine the correct priority sequence for intervention. Three independent contributors are present, all operating through related but distinct mechanisms. Methadone prolongs the QTc through direct blockade of cardiac hERG (IKr — rapid delayed rectifier) potassium channels — a pharmacological effect that is intrinsic to methadone and dose-dependent. Haloperidol also prolongs the QTc through hERG channel blockade — a class effect of many antipsychotics, particularly first-generation agents — and the two drugs have additive effects on QTc when co-administered. Hypokalemia (K⁺ 2.9 mEq/L) reduces the electrochemical driving force for potassium efflux through hERG channels and causes hERG channel inactivation, independently prolonging repolarization; hypomagnesemia (Mg²⁺ 1.4 mg/dL) impairs membrane stabilization and reduces the conductance of multiple repolarizing currents. Together, these electrolyte deficiencies can add 20 to 40 milliseconds or more to the QTc beyond what the drugs alone would produce. The rational priority is to address the most rapidly correctable contributors first — electrolyte repletion can begin immediately and may substantially reduce the QTc within hours — before making irreversible decisions such as discontinuing methadone (which carries significant relapse risk) or reducing haloperidol (which risks psychotic decompensation). Reassessing the QTc after electrolyte correction provides the cleanest picture of the residual drug contribution and informs subsequent dose adjustment decisions.

Option A: Option A is incorrect because methadone does have direct hERG channel activity; there is no kappa receptor mechanism that offsets QT prolongation, and this represents a fabricated pharmacological interaction.
Option B: Option B is incorrect because buprenorphine does have some cardiac ion channel activity at high doses, and characterizing methadone as the sole unmodifiable contributor while dismissing the other factors understates their clinical significance; methadone dose reduction or haloperidol substitution with a lower-risk antipsychotic are both valid options after electrolyte correction.
Option D: Option D is incorrect because ICD implantation is secondary prevention for survivors of ventricular fibrillation or recurrent torsades de pointes — not a first-line intervention for drug-induced QTc prolongation with correctable causes; managing the pharmacological contributors is always the first step.
Option E: Option E is incorrect because both methadone and haloperidol independently prolong the QTc through intrinsic hERG channel activity that does not require co-existing electrolyte abnormalities to be clinically significant; electrolyte correction will reduce QTc but is unlikely to normalize it completely given the pharmacological contributions of both drugs.

2. A 41-year-old man with opioid use disorder has been using illicit methadone obtained from a friend for the past six weeks. He presents requesting buprenorphine induction. His last methadone dose was approximately 30 hours ago. His COWS score (Clinical Opiate Withdrawal Scale — a validated 11-item tool scoring withdrawal severity from 0 to 48) is 10, which typically meets the threshold for buprenorphine induction used for short-acting opioids such as heroin. The clinician is about to administer the first buprenorphine dose when a supervising physician intervenes and advises waiting significantly longer. Which of the following most precisely explains why the standard COWS-guided induction timing used for short-acting opioids is insufficient when the preceding opioid is methadone?

A) Methadone has an exceptionally long and variable half-life of 24 to 80 hours or more; even at 30 hours after the last dose, substantial methadone plasma concentrations remain and methadone continues to occupy mu (μ) receptors; a COWS score of 10 at 30 hours reflects early methadone withdrawal but does not indicate that receptor occupancy has fallen to the low level required for safe buprenorphine induction — administering buprenorphine at this point risks precipitating severe withdrawal as buprenorphine displaces residual methadone from receptors; guidelines recommend waiting at least 72 to 96 hours or until COWS is consistently ≥12 to 16 before initiating buprenorphine after methadone, and low-dose induction protocols are preferred to minimize precipitation risk
B) Methadone is a CYP3A4 inducer that upregulates buprenorphine metabolism; if buprenorphine is given within 48 hours of the last methadone dose, first-pass metabolism of sublingual buprenorphine is accelerated, reducing its plasma concentration to sub-therapeutic levels and making induction impossible until CYP3A4 activity normalizes over 2 to 3 weeks
C) The COWS score is not validated for methadone withdrawal because methadone withdrawal does not produce the autonomic signs (lacrimation, rhinorrhea, diaphoresis) that COWS measures; a specialized methadone-specific withdrawal scale must be used before any buprenorphine induction decision, regardless of the time since last methadone dose
D) Methadone accumulates irreversibly in the mu receptor binding site after chronic use, requiring receptor turnover rather than plasma level decline before buprenorphine can be safely initiated; the waiting period is determined by mu receptor half-life of approximately 7 days, not by methadone plasma pharmacokinetics
E) The risk is not precipitated withdrawal but rather additive respiratory depression; methadone and buprenorphine have synergistic effects on brainstem respiratory centers when plasma levels of both are present simultaneously, and the required waiting period is based on achieving sub-respiratory-depressant methadone plasma levels rather than sub-withdrawal-precipitating receptor occupancy levels

ANSWER: A

Rationale:

This question asked you to explain why COWS-guided induction timing validated for short-acting opioids fails when the preceding opioid is methadone. The core issue is methadone's pharmacokinetics. After heroin or short-acting opioids, plasma levels fall rapidly — within 6 to 12 hours — and a COWS score ≥8 reliably indicates that receptor occupancy has fallen sufficiently for safe buprenorphine induction. Methadone is fundamentally different: its half-life ranges from 24 to 80 hours or longer, and its extensive tissue distribution means that even as plasma levels decline, drug continues to redistribute from peripheral compartments back into the circulation, sustaining receptor occupancy far longer than the COWS score alone would indicate. At 30 hours after the last methadone dose, plasma methadone levels may still be 50% or more of peak — well above the threshold for significant mu receptor occupancy. A COWS score of 10 at this point reflects early withdrawal symptoms as levels begin to fall, not the near-complete receptor vacating required for safe buprenorphine introduction. If buprenorphine is administered, its superior mu receptor affinity allows it to displace residual methadone, but as a partial agonist it produces far less receptor activation than the displaced methadone — precipitating acute, often severe withdrawal that can be more intense than spontaneous methadone withdrawal. Current guidelines recommend waiting at minimum 72 hours from the last methadone dose, with many experts recommending 96 hours or longer for patients on higher methadone doses; low-dose buprenorphine induction protocols (starting at 0.5 to 2 mg and titrating slowly) further reduce precipitation risk.

Option B: Option B is incorrect because methadone is not a CYP3A4 inducer; it is a CYP3A4 substrate, and it does not accelerate buprenorphine metabolism; the pharmacokinetic interaction described is fabricated.
Option C: Option C is incorrect because COWS is validated for opioid withdrawal broadly, including methadone withdrawal; all the autonomic signs it measures occur in methadone withdrawal; the issue is not COWS validity but the inadequacy of using the same threshold timing as for short-acting opioids.
Option D: Option D is incorrect because methadone does not bind irreversibly to mu receptors; its binding is competitive and reversible, and the waiting period is determined by plasma pharmacokinetics, not receptor turnover.
Option E: Option E is incorrect because the primary risk of premature buprenorphine induction after methadone is precipitated withdrawal through receptor displacement, not additive respiratory depression; buprenorphine's partial agonism and ceiling effect on respiratory depression make the additive depression scenario far less clinically significant than withdrawal precipitation.

3. Two mechanically ventilated ICU patients have been receiving continuous opioid infusions for 96 hours. Patient A received fentanyl at 100 mcg/hour; Patient B received remifentanil at an equianalgesic rate. Both infusions are now stopped simultaneously in preparation for spontaneous breathing trials. The intensivist predicts very different weaning trajectories for the two patients. Which of the following most accurately predicts the pharmacokinetic behavior and clinical implication for each patient after infusion termination?

A) Both patients will have identical offset times because both fentanyl and remifentanil are phenylpiperidine opioids with similar receptor binding kinetics; the duration of infusion does not affect offset time for either drug because both undergo first-order elimination independent of context
B) Patient A will wake faster than Patient B because fentanyl's higher lipophilicity produces faster CNS egress after infusion termination; remifentanil's lower lipophilicity causes it to remain in CNS tissue longer despite its short plasma half-life
C) Patient B will have a prolonged wake-up because remifentanil's esterase metabolite GR90291 accumulates during 96-hour infusions and reaches plasma concentrations that maintain mu receptor activation for 4 to 6 hours after the infusion stops
D) Patient A will have a markedly prolonged and unpredictable offset — potentially many hours — because fentanyl's high lipophilicity causes progressive accumulation in peripheral fat and muscle compartments during 96-hour infusion, producing a context-sensitive half-time that has increased from approximately 20 minutes after a brief bolus to several hours after prolonged infusion as peripheral compartments act as a sustained reservoir; Patient B will regain spontaneous ventilation within 10 to 20 minutes because remifentanil's esterase-mediated metabolism produces a context-insensitive half-life of 3 to 10 minutes regardless of infusion duration
E) Patient A's offset will be prolonged by approximately 30 minutes compared to Patient B because fentanyl undergoes saturable CYP3A4 metabolism that becomes zero-order at high plasma concentrations reached during prolonged infusion, while remifentanil bypasses CYP3A4 entirely

ANSWER: D

Rationale:

This question asked you to apply the concept of context-sensitive half-time to predict clinically different offset profiles after prolonged infusions of fentanyl versus remifentanil. Context-sensitive half-time is defined as the time required for plasma drug concentration to fall by 50% after stopping an infusion, as a function of infusion duration. For fentanyl — a highly lipophilic phenylpiperidine — brief infusions produce rapid redistribution-driven offset, with a context-sensitive half-time of approximately 20 minutes after a 1-hour infusion. However, with each passing hour of infusion, fentanyl continues to distribute into peripheral fat and muscle compartments throughout the body, progressively saturating these reservoirs. As the infusion continues, the concentration gradient that initially drove peripheral uptake diminishes, and eventually reverses: when the infusion stops and plasma levels begin to fall, drug diffuses back from loaded peripheral compartments into the plasma, sustaining plasma concentrations and dramatically extending the effective half-time. After 96 hours of infusion, fentanyl's context-sensitive half-time may be 8 to 12 hours or longer, making weaning highly unpredictable. Remifentanil's elimination by nonspecific plasma and tissue esterases is entirely independent of peripheral compartment loading — the enzyme is present throughout the body at concentrations far exceeding what is needed to metabolize even high infusion rates, and esterase activity is not saturable at clinical concentrations. Consequently, remifentanil's effective half-life of 3 to 10 minutes is invariant across infusion durations from 1 hour to 7 days. Patient B is thus predicted to awaken within 10 to 20 minutes, while Patient A faces a prolonged, unpredictable recovery period.

Option A: Option A is incorrect because duration of infusion profoundly affects fentanyl's offset time through peripheral compartment accumulation, while remifentanil is genuinely context-insensitive; the two drugs are not equivalent in this regard despite sharing the phenylpiperidine scaffold.
Option B: Option B is incorrect because the direction of the prediction is inverted; higher lipophilicity in fentanyl produces greater peripheral accumulation and slower offset, not faster CNS egress; it is Patient B (remifentanil) who wakes faster.
Option C: Option C is incorrect because remifentanil's metabolite GR90291 is pharmacologically inactive at mu receptors and does not maintain sedation or respiratory depression after infusion termination, regardless of accumulation; this is one of remifentanil's clinical advantages.
Option E: Option E is incorrect because fentanyl's prolonged offset is due to peripheral compartment redistribution, not saturable CYP3A4 metabolism; CYP3A4 metabolism of fentanyl does not become zero-order at clinical plasma concentrations, and this mechanism does not explain the context-sensitive half-time phenomenon.

4. A 69-year-old man with metastatic colon cancer develops hospital-acquired acute kidney injury (AKI), with creatinine rising from 0.9 to 4.2 mg/dL over 48 hours. He has been receiving scheduled intravenous morphine for pain control and is now deeply sedated with a respiratory rate of 5 breaths per minute despite the morphine dose remaining unchanged. His pain was previously well controlled. The team correctly identifies morphine-6-glucuronide accumulation as the cause and decides to rotate to a different opioid. Ranking the following agents by their suitability in this patient — fentanyl, hydromorphone, oxycodone, and tramadol — which agent is most appropriate and why?

A) Tramadol is the most appropriate choice because it is metabolized entirely by CYP2D6 to an inactive glucuronide that is excreted in bile rather than urine, making its clearance completely independent of renal function; no dose adjustment is required in any degree of renal impairment
B) Fentanyl is the most appropriate choice because its primary metabolite norfentanyl is pharmacologically inactive and does not accumulate to clinically significant concentrations in renal failure; fentanyl clearance is predominantly hepatic and does not produce renally dependent active metabolites that would perpetuate opioid toxicity, making it the safest option among the agents listed for this patient with acute kidney injury
C) Oxycodone is the most appropriate choice because it is exclusively metabolized by CYP2D6 to oxymorphone, which is immediately glucuronidated to an inactive form before renal excretion; active metabolite accumulation does not occur in renal failure because the inactivation step precedes elimination
D) Hydromorphone is equally safe as fentanyl in this patient because hydromorphone-3-glucuronide (H3G), its primary metabolite, has no pharmacological activity at any opioid receptor and therefore cannot produce toxicity regardless of accumulation level in renal failure
E) All four agents are equally contraindicated in acute kidney injury because all opioids produce active glucuronide metabolites that accumulate when GFR (glomerular filtration rate — a measure of kidney filtering capacity) falls; the correct management is complete opioid cessation and transition to non-opioid analgesia until renal function recovers

ANSWER: B

Rationale:

This question asked you to rank opioid agents by safety in acute kidney injury based on their metabolite profiles and renal dependence. Fentanyl is the most appropriate choice among the options listed. Its primary metabolic pathway is CYP3A4-mediated N-dealkylation to norfentanyl, which is pharmacologically inactive at opioid receptors. Norfentanyl does accumulate in renal failure, but because it has no meaningful mu receptor activity, this accumulation does not produce opioid toxicity. Fentanyl's clinical effect therefore does not increase disproportionately as GFR falls, and it can be used with standard monitoring in patients with AKI. Hydromorphone requires caution: hydromorphone-3-glucuronide (H3G) accumulates in renal failure and, while less potent than M6G at opioid receptors, H3G has neuroexcitatory properties — myoclonus, cognitive impairment, and possible seizures at very high concentrations — that make it less ideal than fentanyl in significant renal impairment. Oxycodone produces oxymorphone (an active, potent metabolite) and oxymorphone-3-glucuronide, both of which accumulate in renal failure; oxymorphone accumulation increases the risk of dose-dependent opioid toxicity. Tramadol is contraindicated in significant renal impairment: both tramadol and its active opioid metabolite O-desmethyltramadol (M1) accumulate, increasing seizure risk and serotonergic toxicity, and the drug's prescribing information includes a specific contraindication for eGFR below 30 mL/min.

Option A: Option A is incorrect because tramadol is not metabolized to an inactive biliary-excreted glucuronide; it produces the active opioid metabolite M1 via CYP2D6, and both tramadol and M1 accumulate in renal failure; tramadol is specifically contraindicated in significant renal impairment.
Option C: Option C is incorrect because oxycodone's CYP2D6-derived metabolite oxymorphone is pharmacologically active and potent; it is not immediately inactivated before renal excretion; active oxymorphone accumulates in renal failure and contributes to toxicity.
Option D: Option D is incorrect because while H3G has no significant mu opioid receptor activity, it does have neuroexcitatory properties at high concentrations including myoclonus and cognitive disturbances, making hydromorphone less safe than fentanyl in significant renal impairment, not equally safe.
Option E: Option E is incorrect because not all opioids produce clinically significant active metabolite accumulation in renal failure; fentanyl specifically does not, and complete opioid cessation in a patient with metastatic cancer pain is neither necessary nor appropriate when a safe alternative exists.

5. A 27-year-old woman is brought to the emergency department after taking approximately 3,000 mg of tramadol in a suicide attempt (her prescribed dose is 50 mg four times daily). On arrival she is obtunded with a respiratory rate of 8 breaths per minute, miosis, and GCS (Glasgow Coma Scale — a measure of neurological status scored 3 to 15) of 10. She is given naloxone 0.4 mg IV, which partially improves her respiratory rate to 12 breaths per minute and raises her GCS to 13. Thirty minutes later she develops agitation, diaphoresis, clonus (rhythmic muscle contractions triggered by rapid joint extension), and a temperature of 38.9°C. Which of the following most accurately explains the biphasic toxicity in this patient and identifies the correct management of the second syndrome?

A) The initial presentation represents mu opioid toxicity from tramadol's weak opioid agonism; the second syndrome represents a paradoxical naloxone-induced catecholamine surge causing adrenergic toxidrome; management requires alpha-1 adrenergic blockade with phentolamine and cessation of naloxone
B) Both presentations represent opioid toxicity; the second syndrome occurs because naloxone's short half-life allowed tramadol's opioid effect to re-emerge as naloxone was metabolized; management requires a naloxone infusion at 2/3 of the effective bolus dose per hour to maintain continuous opioid reversal
C) The initial presentation represents opioid toxicity; the second syndrome represents tramadol-induced seizure activity misidentified as serotonin syndrome; the correct management is phenytoin for seizure prophylaxis and continued naloxone infusion for the opioid component
D) Both syndromes are caused by normeperidine-like proconvulsant metabolites of tramadol that accumulate after massive overdose; the second syndrome is normeperidine toxicity and should be treated with benzodiazepines; naloxone should be discontinued as it worsens stimulant toxicity
E) The initial presentation represents mu opioid receptor-mediated CNS and respiratory depression from tramadol's weak opioid agonism and O-desmethyltramadol (M1) accumulation, partially reversed by naloxone; the second syndrome represents serotonin syndrome precipitated by the massive dose of tramadol's serotonin reuptake inhibition component, unmasked as the opioid depression was reversed; management requires cyproheptadine (a serotonin receptor antagonist) or benzodiazepines for agitation and neuromuscular features, cooling for hyperthermia, and avoidance of opioid reversal agents that could further unmask the serotonergic toxicity

ANSWER: E

Rationale:

This question asked you to identify and manage the two mechanistically distinct toxicity syndromes produced by tramadol overdose. Tramadol's dual pharmacological mechanism — weak mu opioid agonism and serotonin/norepinephrine reuptake inhibition — produces two overlapping but distinct toxicity profiles in overdose. At presentation, the dominant picture is mu opioid toxicity from tramadol and its active opioid metabolite O-desmethyltramadol (M1): CNS depression, respiratory depression, and miosis. This component is naloxone-responsive, and partial improvement confirms its opioid basis. However, tramadol also inhibits serotonin reuptake transporters — an intrinsic property of the parent compound — and in massive overdose, the resulting serotonin excess produces serotonin syndrome. The classic triad of serotonin syndrome — altered mental status, autonomic instability (hyperthermia, diaphoresis, tachycardia), and neuromuscular abnormalities (clonus, hyperreflexia, rigidity) — emerges as the opioid depression is lifted by naloxone, unmasking the serotonergic toxicity that was previously obscured. Management of the serotonergic component requires: cyproheptadine (a 5-HT2A receptor antagonist that directly blocks the serotonin excess) given orally or via NG tube, benzodiazepines for agitation and neuromuscular activity, external cooling for hyperthermia, and avoidance of further naloxone administration which risks deepening the serotonin syndrome by more fully unmasking it. Critically, opioid antagonists do not treat serotonin syndrome and may worsen the clinical picture if given aggressively after the opioid component has been adequately reversed.

Option A: Option A is incorrect because the second syndrome is serotonin syndrome — not a catecholamine surge from naloxone — and phentolamine has no role in serotonin syndrome management; adrenergic toxidrome and serotonin syndrome are distinct entities with different management.
Option B: Option B is incorrect because the second syndrome is not re-emerging opioid toxicity; its features — clonus, hyperthermia, agitation, diaphoresis — are not opioid toxicity features, and a naloxone infusion would not address the serotonergic component.
Option C: Option C is incorrect because clonus in this context is a hallmark of serotonin syndrome, not isolated seizure activity; phenytoin is ineffective for serotonin syndrome and would not address the mechanism; the correct anti-serotonergic agent is cyproheptadine.
Option D: Option D is incorrect because tramadol does not produce normeperidine-like metabolites; this is a fabricated mechanism; the second syndrome is serotonin syndrome from tramadol's intrinsic reuptake inhibition, not a normeperidine-type stimulant toxicity.

6. A 53-year-old woman with chronic cancer pain has been stable on methadone 40 mg daily for three months. Feeling her pain was worsening, she independently increased her dose to 60 mg daily one week ago without notifying her prescriber. She reports the first two days felt better, days three through five she felt "a little drowsy," and on day seven she is brought to the emergency department unresponsive with a respiratory rate of 3 breaths per minute. Her family is confused about why she deteriorated progressively over a week despite taking the same higher dose throughout. Which of the following most precisely explains the pharmacokinetic basis for this timeline of progressive toxicity?

A) Methadone undergoes autoinduction of CYP3A4 at doses above 50 mg daily; at her new dose, CYP3A4 was induced during the first two days, then saturated by day three, causing plasma methadone levels to rise exponentially from day three onward as the auto-induction enzyme became overwhelmed
B) The 50% dose increase from 40 mg to 60 mg crossed a pharmacodynamic threshold at which methadone's NMDA receptor antagonism becomes fully saturated, shifting its dominant effect from analgesia to respiratory depression through an abrupt receptor-level mechanism that manifests over 5 to 7 days as receptor saturation progresses
C) Methadone is absorbed erratically from the gastrointestinal tract, and variability in absorption produces an unpredictable accumulation pattern; the day-7 toxicity represents a chance episode of complete gastrointestinal absorption coinciding with a prior partially-absorbed dose producing an additive peak
D) Methadone's long and variable half-life — commonly 30 to 60 hours or longer in many patients — means that after a dose increase, plasma concentrations do not reach steady state for approximately 4 to 5 half-lives; during this accumulation phase, methadone levels rise with every dose even though the daily dose is constant; initial days feel improved because analgesic levels are achieved before toxic levels; by days five to seven, continuing accumulation reaches the toxic threshold, producing progressive sedation and ultimately respiratory arrest — a timeline entirely consistent with a half-life of 48 hours approaching steady state at 10 days
E) The progressive toxicity results from competitive displacement of methadone from plasma protein binding sites by endogenous fatty acids that accumulate as nutritional intake declines with increasing sedation; each day of reduced eating increases free methadone fraction, amplifying toxicity in a self-reinforcing cycle independent of total methadone dose

ANSWER: D

Rationale:

This question asked you to apply methadone pharmacokinetics to explain a clinical timeline of progressive delayed toxicity. The mechanism is entirely explained by methadone's long and variable half-life and the time required to reach steady state after a dose change. For any drug following first-order kinetics, steady-state plasma concentration is reached after approximately 4 to 5 half-lives. Methadone's half-life varies widely — commonly 24 to 80 hours, with many patients having half-lives of 30 to 60 hours. Using a representative half-life of 48 hours: steady state would not be reached until approximately 10 days after the dose change (5 × 48 hours). During this accumulation phase, plasma methadone concentration rises with every dose. The clinical timeline in this patient is textbook: days one to two produced improved analgesia as plasma levels rose from the previous sub-analgesic baseline toward the therapeutic range; days three to five produced early CNS depression as levels continued rising through and above the therapeutic range; by day seven, with levels still rising toward a new — and for this patient, toxic — steady state, respiratory depression became life-threatening. This pattern is not unique to self-dose escalation; it is the same mechanism responsible for toxicity when clinicians increase methadone doses too frequently without allowing adequate time for steady state assessment. The clinical rule is to wait at least 5 to 7 days between methadone dose adjustments, and to monitor closely throughout the accumulation period.

Option A: Option A is incorrect because methadone does not cause CYP3A4 autoinduction; it is a CYP3A4 substrate, not an inducer, and enzyme saturation producing exponential level rise is not an established pharmacokinetic mechanism for methadone.
Option B: Option B is incorrect because there is no pharmacodynamic threshold at which NMDA receptor saturation abruptly converts analgesia to respiratory depression; NMDA antagonism and mu receptor-mediated respiratory depression are separate mechanisms, and the progressive timeline is explained by pharmacokinetics, not a receptor-level switch.
Option C: Option C is incorrect because methadone has relatively consistent oral bioavailability (approximately 80%); erratic absorption producing a chance additive peak on day seven is not consistent with the progressive worsening described and does not explain the week-long accumulation trajectory.
Option E: Option E is incorrect because plasma protein displacement by endogenous fatty acids from reduced nutritional intake is not an established mechanism of progressive methadone toxicity; this represents a fabricated pharmacokinetic interaction that does not occur clinically.

7. A clinical pharmacologist is discussing codeine pharmacogenetics with a global health team. She notes that the clinical consequences of CYP2D6 ultrarapid metabolizer status vary dramatically by geographic region and population, and that this has important implications for codeine prescribing in certain parts of the world. Which of the following most accurately describes the population distribution of CYP2D6 ultrarapid metabolizers and the clinical consequence that is most pronounced in high-prevalence regions?

A) CYP2D6 ultrarapid metabolizer prevalence is highest in East Asian populations (approximately 40 to 50%); the primary clinical consequence in these populations is codeine treatment failure because excess morphine production triggers rapid mu receptor downregulation, producing tolerance within the first dose and complete loss of analgesia with repeated use
B) CYP2D6 ultrarapid metabolizer prevalence is uniformly distributed across all ethnic populations at approximately 3 to 5%; the clinical consequence is identical worldwide — a modest increase in morphine production that requires no dose adjustment but necessitates closer monitoring for respiratory depression in neonates of breastfeeding women
C) CYP2D6 ultrarapid metabolizer prevalence varies substantially by ethnicity — approximately 1 to 2% in East Asian populations, 3 to 5% in Northern European populations, but 16 to 29% in some North African and Ethiopian populations (particularly among Ethiopians where gene duplication alleles are highly prevalent); in high-prevalence regions, codeine at standard doses produces morphine concentrations sufficient to cause serious toxicity or death, making codeine an inappropriately risky analgesic for standard clinical use without pharmacogenetic screening
D) CYP2D6 ultrarapid metabolizer status is most clinically significant in CYP2D6 poor metabolizer populations, where the two phenotypes interact genetically; the highest combined prevalence occurs in South Asian populations where both phenotypes co-exist, producing a bimodal distribution of codeine response
E) CYP2D6 ultrarapid metabolizers are most prevalent in populations with high dietary consumption of CYP2D6-inducing compounds found in cruciferous vegetables; the prevalence is therefore highest in Northern European populations with high cabbage consumption, where codeine toxicity risk correlates with dietary patterns rather than genetic polymorphism

ANSWER: C

Rationale:

This question asked you to apply knowledge of CYP2D6 pharmacogenetics to a global health context, requiring precise recall of population prevalence data and clinical consequence. CYP2D6 ultrarapid metabolizer (UM) status arises primarily from gene duplication events producing multiple functional copies of the CYP2D6 gene, resulting in enzyme activity far exceeding normal. The prevalence of the UM phenotype varies dramatically across ethnic populations: it is rare in East Asian populations (approximately 1 to 2%, reflecting the low frequency of gene duplication alleles in these populations); intermediate in Northern European and North American populations (approximately 3 to 5%); and strikingly high in certain North African and Ethiopian populations, where prevalence reaches 16 to 29% in some studies. In Ethiopian populations specifically, CYP2D6 gene duplications are highly prevalent, meaning that a substantial proportion of patients prescribed standard codeine doses will generate morphine plasma concentrations equivalent to receiving morphine directly at several times the codeine dose equivalent. The clinical consequence is not subtle: in a population where 20% of patients are ultrarapid metabolizers, standard codeine prescribing exposes one in five patients to serious opioid toxicity risk. This epidemiological reality explains why some national prescribing guidelines in high-prevalence regions have moved to discourage or prohibit codeine use without pharmacogenetic guidance.

Option A: Option A is incorrect because CYP2D6 ultrarapid metabolizer prevalence in East Asian populations is actually among the lowest globally (1 to 2%), not the highest; and the clinical consequence of ultrarapid metabolism is excess morphine production causing toxicity, not rapid tolerance from receptor downregulation.
Option B: Option B is incorrect because CYP2D6 ultrarapid metabolizer prevalence is emphatically not uniform across populations at 3 to 5%; the population-level variation is clinically and pharmacoepidemiologically significant, ranging from 1 to 2% to nearly 30% across different ethnic groups.
Option D: Option D is incorrect because CYP2D6 ultrarapid and poor metabolizer phenotypes are independent genetic variants that do not interact genetically to produce a combined high-prevalence population in South Asians; these are distinct allelic variants that segregate independently.
Option E: Option E is incorrect because CYP2D6 ultrarapid metabolizer status is determined by germline gene copy number variation, not by dietary induction of enzyme activity; cruciferous vegetables affect CYP1A2 and to some extent CYP3A4 but do not produce the gene duplication-based ultrarapid phenotype relevant to codeine.

8. A 32-year-old man with known opioid use disorder is found unresponsive at home. Empty blister packs of oxycodone extended-release 80 mg tablets are found nearby, along with a spoon and residue suggesting the tablets were crushed and dissolved. Toxicology confirms oxycodone at a concentration consistent with massive acute overdose. A medical student asks how crushing an extended-release tablet produces a qualitatively different — and more dangerous — overdose than taking the same number of intact tablets. Which of the following most accurately explains the pharmacokinetic mechanism and its clinical consequence?

A) Extended-release oxycodone tablets contain the full 80 mg dose within a controlled-release polymer matrix designed to deliver drug slowly over 12 hours, limiting peak plasma concentration; crushing destroys the matrix and converts the formulation to immediate-release, delivering the entire 80 mg dose within 30 to 60 minutes — a dose-dumping effect that produces peak plasma oxycodone concentrations 5 to 10 times higher than intact tablet administration, overwhelming mu receptor-mediated respiratory center control and producing fatal respiratory depression at a dose that would be survivable if absorbed gradually
B) Extended-release oxycodone contains an inactive prodrug form that is activated only by intestinal esterases acting over 12 hours; crushing exposes the active drug simultaneously across all particles, causing immediate enzymatic activation and simultaneous release of all active oxycodone within minutes of administration
C) Crushing extended-release oxycodone accelerates CYP3A4-mediated conversion to oxymorphone by increasing the surface area available for hepatic enzyme contact; the resulting immediate high oxymorphone concentrations — rather than oxycodone itself — are responsible for the fatal toxicity
D) Extended-release tablets contain a naloxone coating that is stripped away by the crushing process; without the naloxone barrier, oxycodone is absorbed without its built-in antagonist protection, producing unantagonized opioid receptor activation
E) Crushing extended-release oxycodone exposes the drug to gastric acid, converting oxycodone to a more lipophilic acid-stable form with 10-fold greater blood-brain barrier penetration than native oxycodone, producing CNS concentrations far exceeding what intact tablet absorption would achieve

ANSWER: A

Rationale:

This question asked you to explain the pharmacokinetic basis for the enhanced lethality of tampered extended-release opioid formulations. Extended-release (ER) opioid tablets are engineered to control the rate of drug release through polymer matrix technology, membrane coating, or osmotic pump mechanisms. An oxycodone ER 80 mg tablet contains the full 80 mg dose, but the formulation is designed to release it gradually over approximately 12 hours, maintaining plasma concentrations within the therapeutic range while avoiding the high peak concentrations that produce respiratory depression. When the tablet is crushed, the controlled-release architecture is mechanically destroyed: the entire 80 mg dose becomes immediately available for dissolution and absorption, producing dose dumping — the rapid delivery of the complete dose as if it were an immediate-release tablet. The resulting peak plasma oxycodone concentration may be 5 to 10 times higher than that achieved with the intact formulation, occurring within 30 to 60 minutes rather than being spread over 12 hours. This dramatically elevated peak concentration overwhelms the brainstem mu receptor-mediated respiratory drive and produces acute respiratory failure at a total dose that, absorbed slowly over 12 hours, would be within the tolerant patient's safety margin. This pharmacokinetic manipulation — dose dumping through physical tampering — is the basis for the abuse-deterrent formulations subsequently developed, which use technologies such as polyethylene oxide matrices that form a viscous gel when wet (preventing injection) and resist crushing.

Option B: Option B is incorrect because oxycodone is not an inactive prodrug activated by intestinal esterases; it is pharmacologically active as administered and does not require intestinal enzymatic conversion for efficacy — unlike codeine or tramadol.
Option C: Option C is incorrect because crushing the tablet does not accelerate hepatic CYP3A4 metabolism; CYP3A4 activity is an intrinsic property of the liver, not influenced by the physical form of the orally administered drug; and oxymorphone toxicity rather than oxycodone toxicity is not the pharmacological explanation for the overdose.
Option D: Option D is incorrect because standard oxycodone extended-release tablets do not contain a naloxone coating; naloxone-containing opioid formulations (such as Targiniq — oxycodone-naloxone) are a distinct product class, and this is not the mechanism at work in standard ER oxycodone.
Option E: Option E is incorrect because gastric acid does not convert oxycodone to a more lipophilic blood-brain barrier-penetrant form; this is a fabricated chemical conversion mechanism that does not represent established oxycodone pharmacology.

9. A pharmacology instructor presents two clinical scenarios to illustrate why butorphanol — a mixed kappa agonist and partial mu agonist or antagonist — produces dramatically different responses depending on the patient's opioid exposure history. Scenario 1: an opioid-naive patient with migraine receives intranasal butorphanol. Scenario 2: a patient physically dependent on long-term oxycodone for chronic pain receives butorphanol for an acute pain exacerbation. Which of the following most accurately predicts and explains the contrasting responses in these two patients?

A) In the opioid-naive patient, butorphanol produces no analgesia because kappa receptor agonism only produces analgesia in patients with pre-existing opioid tolerance; in the opioid-dependent patient, butorphanol acts as a full mu agonist by upregulating mu receptors through a tolerance-reversal mechanism, producing excellent analgesia
B) In both patients, butorphanol produces identical analgesia through kappa receptor agonism; the only difference is that the opioid-dependent patient requires a 50% higher dose to achieve the same kappa receptor occupancy due to cross-tolerance between mu and kappa receptors from chronic oxycodone exposure
C) In the opioid-naive patient, butorphanol produces profound respiratory depression exceeding that of full agonists because the kappa receptor has no ceiling effect on respiratory depression; in the opioid-dependent patient, butorphanol produces no respiratory depression due to mu receptor tolerance providing cross-protection at the kappa receptor
D) In the opioid-naive patient, butorphanol produces effective analgesia through kappa receptor agonism combined with partial mu agonism, with a ceiling on respiratory depression making it relatively safe; in the opioid-dependent patient, butorphanol's mu receptor antagonist component displaces oxycodone from occupied mu receptors and — as a partial agonist producing far less receptor activation than the displaced full agonist — precipitates acute opioid withdrawal, potentially with severe dysphoria from unopposed kappa agonism superimposed on the withdrawal state
E) In the opioid-naive patient, butorphanol causes severe dysphoria and psychotomimetic effects that preclude clinical use; in the opioid-dependent patient, mu receptor downregulation from chronic oxycodone eliminates the dysphoric kappa receptor response and butorphanol is well tolerated and effective

ANSWER: D

Rationale:

This question asked you to contrast butorphanol's pharmacodynamic profile in an opioid-naive versus an opioid-dependent patient, applying knowledge of mixed agonist-antagonist receptor pharmacology. In the opioid-naive patient (Scenario 1), butorphanol behaves as expected for a mixed agonist-antagonist: kappa receptor agonism produces analgesia and some sedation; partial mu receptor activity contributes additional analgesia; and the ceiling effect on respiratory depression (inherent to partial agonism) makes it safer than full agonists in this population. Intranasal butorphanol for migraine exploits these properties — rapid onset, effective analgesia, limited respiratory risk. In the opioid-dependent patient (Scenario 2), the clinical picture is dramatically different. The patient has been chronically exposed to oxycodone, a full mu agonist, and has developed physical dependence — the nervous system has neuroadapted to require ongoing mu receptor activation. When butorphanol is administered, its mu receptor antagonist component competitively displaces oxycodone from mu receptors; as a partial agonist, it produces far less receptor activation than the oxycodone it displaced, effectively creating a sudden deficit in mu receptor tone that precipitates acute withdrawal. This withdrawal state is then compounded by butorphanol's kappa agonism: kappa receptor activation produces dysphoria, anxiety, and psychotomimetic effects that are particularly distressing in the context of simultaneous withdrawal — a combined pharmacodynamic catastrophe. This is the same mechanism underlying the contraindication of all mixed agonist-antagonists in physically opioid-dependent patients.

Option A: Option A is incorrect because kappa receptor agonism produces analgesia in opioid-naive patients — it does not require pre-existing tolerance; and butorphanol does not act as a full mu agonist through a tolerance-reversal mechanism in opioid-dependent patients.
Option B: Option B is incorrect because there is not symmetric cross-tolerance between mu and kappa receptors that would simply require a 50% dose increase in dependent patients; the responses are qualitatively different — withdrawal precipitation, not merely reduced analgesia.
Option C: Option C is incorrect because butorphanol's kappa receptor agonism does have a ceiling effect on respiratory depression, and mu receptor tolerance does not provide cross-protection at kappa receptors; the directions of the predicted responses are pharmacologically inverted.
Option E: Option E is incorrect because while kappa-mediated dysphoria is a recognized side effect of butorphanol and other kappa agonists, it occurs in opioid-naive patients at clinically used doses; and mu receptor downregulation in opioid-dependent patients does not eliminate kappa receptor-mediated dysphoria — kappa and mu receptors are distinct receptor populations.

10. A palliative care fellow is selecting between sublingual buprenorphine and transdermal buprenorphine patches for an 81-year-old woman with moderate cancer pain who has difficulty with sublingual medications due to xerostomia (dry mouth) and compliance concerns. She has no history of opioid use disorder. The fellow asks about the pharmacokinetic and clinical differences between the two formulations. Which of the following most accurately contrasts sublingual and transdermal buprenorphine in terms of bioavailability, onset, dose range, and clinical use case?

A) Transdermal buprenorphine has higher bioavailability than sublingual because it completely avoids first-pass hepatic metabolism; sublingual buprenorphine undergoes 70% first-pass extraction on absorption through the sublingual mucosa, making transdermal the preferred route for all buprenorphine indications including opioid use disorder treatment
B) Sublingual buprenorphine achieves bioavailability of approximately 30 to 50% by bypassing first-pass hepatic metabolism via sublingual venous absorption, with onset within 30 to 60 minutes and dose ranges reaching 16 to 32 mg daily for opioid use disorder treatment; transdermal buprenorphine bypasses first-pass metabolism through skin absorption, achieving steady-state over 12 to 24 hours with patch changes every 7 days, bioavailability of approximately 15%, and dose ranges of 5 to 20 mcg/hour appropriate for moderate chronic pain — but not at doses sufficient for opioid use disorder treatment; for this patient with xerostomia and moderate pain without opioid use disorder, transdermal buprenorphine is a pharmacologically appropriate and practically advantageous formulation
C) Sublingual and transdermal buprenorphine have identical bioavailability of approximately 50% because both routes avoid first-pass metabolism entirely; the only clinically relevant difference is onset time — sublingual within 30 minutes versus transdermal requiring 3 days — and the choice between them is based purely on patient preference rather than pharmacokinetic or dose-range considerations
D) Transdermal buprenorphine is contraindicated in patients over 75 years because age-related thinning of the stratum corneum produces uncontrolled absorption rates that cannot be predicted; sublingual buprenorphine is the only safe formulation in elderly patients because absorption through oral mucosa is not affected by age-related skin changes
E) Transdermal buprenorphine is metabolized by skin esterases to an active metabolite with 5 times the mu receptor affinity of buprenorphine; this metabolite provides most of the analgesic effect and accumulates in the dermis, producing a sustained analgesic depot that lasts 14 days after patch removal — an advantage in patients with compliance difficulties

ANSWER: B

Rationale:

This question asked you to compare the pharmacokinetic profiles of sublingual and transdermal buprenorphine and apply this comparison to an appropriate clinical selection. Sublingual buprenorphine achieves bioavailability of approximately 30 to 50% by absorbing through the sublingual venous plexus directly into the systemic circulation, bypassing intestinal and hepatic first-pass metabolism. Onset of effect is within 30 to 60 minutes. The dose range available sublingually is wide — from 0.2 mg to 32 mg or more — making it suitable for opioid use disorder treatment at doses of 8 to 32 mg daily and for acute or moderate pain at lower doses. Transdermal buprenorphine (available as patches delivering 5, 10, 15, or 20 mcg/hour, changed weekly) also avoids first-pass metabolism, but drug absorption through the stratum corneum is slower and bioavailability is lower (approximately 15%). Steady-state plasma concentrations are reached over 12 to 24 hours after patch application. The dose range available transdermally — maximum approximately 20 mcg/hour — is insufficient for opioid use disorder treatment, which requires plasma buprenorphine levels achievable only at the higher sublingual doses. However, for moderate chronic pain management in a patient without opioid use disorder, the transdermal patch delivers adequate analgesic buprenorphine levels without the swallowing or mucosal dissolution requirements that create barriers for this patient with xerostomia. The practical advantages — weekly dosing, no dissolution requirement, no diversion-concern formulation — make transdermal the appropriate choice for this clinical scenario.

Option A: Option A is incorrect because sublingual buprenorphine does not undergo 70% first-pass extraction through the sublingual mucosa; the sublingual route is specifically chosen because it bypasses first-pass metabolism; both routes avoid first-pass metabolism.
Option C: Option C is incorrect because sublingual and transdermal buprenorphine do not have identical bioavailability; sublingual achieves approximately 30 to 50% while transdermal achieves approximately 15%; and the dose ranges are not interchangeable — transdermal doses are insufficient for opioid use disorder treatment.
Option D: Option D is incorrect because transdermal buprenorphine is not contraindicated in elderly patients due to uncontrolled stratum corneum thinning; age-related skin changes require monitoring but do not constitute a contraindication; transdermal buprenorphine is used in the elderly with appropriate monitoring.
Option E: Option E is incorrect because transdermal buprenorphine is not metabolized by skin esterases to a more potent active metabolite; buprenorphine is absorbed intact through the skin and metabolized systemically by CYP3A4; there is no 14-day dermal depot effect from a skin metabolite.

11. A 78-year-old man with chronic kidney disease (eGFR 19 mL/min/1.73m²) has received meperidine 50 mg IV every 3 hours for 5 days following abdominal surgery. He develops myoclonic jerks and increasing agitation. A new nurse, recognizing opioid side effects, administers naloxone 0.8 mg IV. Within 3 minutes the patient has a generalized tonic-clonic seizure lasting 2 minutes, followed by a second seizure. He is now more agitated and tremulous than before the naloxone was given. The senior resident explains to the team exactly why naloxone worsened this patient's condition. Which of the following most precisely explains the mechanism by which naloxone administration precipitated seizures in this patient?

A) Naloxone crossed the blood-brain barrier and directly activated NMDA receptors (N-methyl-D-aspartate subtype glutamate receptors) in cortical neurons by displacing endogenous opioid peptides that normally suppress NMDA receptor activity, generating a seizure through glutamatergic hyperexcitability
B) Naloxone's short half-life of 60 to 90 minutes caused rapid opioid reversal followed by rebound mu receptor supersensitivity within 3 minutes, generating an acute abstinence syndrome that lowered the seizure threshold through noradrenergic hyperactivation from locus coeruleus rebound
C) Naloxone irreversibly binds mu receptors and prevents endogenous opioid peptides from exerting any inhibitory effect; without endogenous opioid-mediated inhibition, cortical excitability increased to the seizure threshold within minutes
D) The 0.8 mg naloxone dose was supratherapeutic and directly activated sigma receptors (non-opioid receptors that mediate psychotomimetic and proconvulsant effects) at the high plasma concentrations achieved immediately after intravenous bolus administration
E) Normeperidine — meperidine's N-demethylated metabolite that had been accumulating for 5 days in this patient with severely impaired renal clearance — exerts its neurotoxicity through non-opioid proconvulsant mechanisms; meperidine's residual mu receptor-mediated CNS depression was partially offsetting normeperidine's stimulant effect; naloxone reversed this protective opioid depression, fully unmasking normeperidine's proconvulsant activity and precipitating seizures — a worsening that is intrinsic to the pharmacology and not a dose error

ANSWER: E

Rationale:

This question asked you to explain the precise mechanism by which naloxone worsened normeperidine toxicity, integrating knowledge of meperidine's metabolite pharmacology with opioid receptor pharmacodynamics. After 5 days of meperidine at 50 mg every 3 hours in a patient with an eGFR of 19 mL/min/1.73m², normeperidine has accumulated to toxic concentrations — its half-life of 15 to 20 hours is further extended by severely impaired renal clearance, and 5 days of dosing has produced progressive accumulation. Normeperidine is not an opioid receptor agonist; it exerts its neurotoxicity through non-opioid mechanisms including inhibition of GABAergic (gamma-aminobutyric acid-mediated inhibitory) interneuron activity and possibly direct proconvulsant membrane channel effects. Simultaneously, the parent meperidine — still present at appreciable plasma concentrations — continues to produce some degree of mu receptor-mediated CNS depression: sedation, reduced arousal, and general CNS suppression. This residual opioid-mediated depression, while not therapeutic, was acting as a pharmacodynamic counterbalance to normeperidine's stimulant and proconvulsant activity — partially attenuating the clinical expression of normeperidine toxicity. When naloxone was administered, it rapidly and competitively displaced meperidine from mu receptors throughout the CNS, eliminating the residual opioid depression within minutes. Without this counterbalancing depression, normeperidine's full proconvulsant effect was unmasked abruptly — the patient's pre-naloxone myoclonus and agitation escalated to frank seizures. This is not a dose error or an unexpected adverse effect of naloxone; it is a predictable pharmacodynamic consequence of removing opioid-mediated suppression from a patient in whom a non-opioid proconvulsant has already accumulated to toxic levels. The correct management of normeperidine toxicity is benzodiazepines for seizure control, meperidine discontinuation, and — critically — avoidance of naloxone.

Option A: Option A is incorrect because naloxone does not directly activate NMDA receptors; it is a pure opioid receptor competitive antagonist with no established direct agonist activity at NMDA or other excitatory receptors.
Option B: Option B is incorrect because rebound mu receptor supersensitivity causing locus coeruleus noradrenergic hyperactivation is a mechanism of opioid withdrawal syndrome that develops over hours to days, not within 3 minutes of naloxone administration; the seizures in this patient occurred within 3 minutes and are explained by normeperidine unmasking, not abstinence syndrome.
Option C: Option C is incorrect because naloxone does not irreversibly bind mu receptors; it is a competitive, reversible antagonist; and endogenous opioid peptide inhibition is not the primary mechanism maintaining seizure threshold in this patient — the relevant dynamic is normeperidine accumulation counterbalanced by meperidine's opioid depression.
Option D: Option D is incorrect because naloxone does not activate sigma receptors at clinical doses; its pharmacological activity is confined to opioid receptors (mu, kappa, delta), and sigma receptor activation is not an established mechanism of naloxone-associated seizures.